Moffitt Notice of Blackbaud Data Incident. Learn More
Your Uterine Cancer Specialists
The uterine cancer specialists in the gynecological clinic at Moffitt Cancer Center offer a comprehensive range of diagnostic and treatment options for endometrial cancer. Guided by evidence-based clinical pathways, our multispecialty tumor board works collaboratively to design a highly individualized treatment plan for this relatively rare condition, which develops in the cells that line the uterus.
In a single location, Moffitt’s patients have access to a collaborative team of uterine cancer specialists, including highly experienced subspecialists in the prevention, diagnosis, genetic sequencing and treatment of gynecologic cancers. Our tumor board is made up of:
- Fellowship-trained surgeons
- Medical oncologists
- Radiation oncologists
- Fertility preservation specialists
- Other supportive care providers
Moffitt’s uterine cancer specialists meet weekly to review each new patient’s treatment options, then monitor each patient’s progress on an ongoing basis, recommending refinements to her treatment plan as necessary. In this way, every patient benefits from multiple expert opinions without the need to request referrals or travel to various physician’s offices and health care centers. Together at Moffitt, a patient and her treatment team decide on the optimal way to proceed.
The uterine cancer specialists at Moffitt continue to transform the treatment of endometrial cancer for all current and future patients. A nationally recognized leader in cancer research, Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida. Moffitt received Highest Ranked in Gynecology in Florida by U.S. News & World Report in 2020.
With a firm commitment to quickly translating the scientific knowledge we gain in the laboratory into tangible patient benefits, Moffitt takes a unique “bench-to-bedside” approach. For instance, through our robust clinical trials program, our patients have opportunities to access promising new treatments before those options are made available in other settings. As a result, our patient outcomes and quality of life consistently exceed the national averages.